ArticleMedicine2026
Rapid progression of cardiovascular-kidney-metabolic syndrome drives accelerated frailty trajectories: A longitudinal cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of dynamic cardiovascular-kidney-metabolic (CKM) syndrome progression on longitudinal frailty trajectories remains unclear. This study investigated how rapid CKM worsening influences adverse frailty index development. We analyzed 3090 community-dwelling adults (baseline CKM stages 1-3, non-frail). CKM progression over 4 years was categorized as stable/improved, mild (+1 stage), or rapid (≥2 stages). Growth mixture modeling identified latent frailty index trajectories over a 7-year follow-up. Growth mixture modeling identified 2 trajectories: "Stable Progressive" (93.5%) and "Accelerated Adverse" (6.5%). Multivariable analysis revealed that rapid CKM progression significantly increased the risk of the "Accelerated Adverse" trajectory (OR = 2.44; 95% CI: 1.56-3.83) compared to the stable/improved group. Notably, mild progression showed no significant association. Rapid CKM stage deterioration independently predicts accelerated frailty worsening. Incorporating dynamic CKM changes into clinical risk assessments is crucial for preventing the transition from cardiometabolic multimorbidity to severe frailty.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.